CareDx, Inc (CDNA) Financial Ratios
14 years of historical data (2012–2025) · Healthcare · Medical - Diagnostics & Research
EV/EBITDA
N/A
—
5yr avg: 18.60
30Y Low18.6·High24.0
P/FCF
↓
30.66
-7% vs avg
5yr avg: 33.10
30Y Low27.8·High146.0
P/B Ratio
↓
3.77
↑+22% vs avg
5yr avg: 3.10
30Y Low1.4·High12.1
ROE
↑
-6.3%
↓+55% vs avg
5yr avg: -14.0%
30Y Low-160%·High16%
Debt/EBITDA
N/A
—
5yr avg: 0.47
30Y Low0.5·High6.5
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
CDNA Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
CareDx, Inc currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis. On a free-cash-flow basis, the stock trades at 30.7x P/FCF, 7% below the 5-year average of 33.1x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.1B | $1.0B | $1.2B | $645M | $608M | $2.4B | $3.4B | $909M | $896M | $171M | $45M |
| Enterprise Value | $1.1B | $958M | $1.1B | $597M | $557M | $2.0B | $3.3B | $876M | $832M | $188M | $51M |
| P/E Ratio → | -53.60 | — | 23.02 | — | — | — | — | — | — | — | — |
| P/S Ratio | 2.92 | 2.64 | 3.63 | 2.30 | 1.89 | 8.02 | 17.52 | 7.16 | 11.70 | 3.54 | 1.10 |
| P/B Ratio | 3.77 | 3.31 | 3.20 | 2.47 | 1.41 | 5.10 | 12.13 | 9.18 | 9.34 | — | 2.25 |
| P/FCF | 30.66 | 27.80 | 38.41 | — | — | — | 145.97 | — | — | — | — |
| P/OCF | 26.35 | 23.89 | 31.86 | — | — | — | 100.73 | — | — | — | — |
P/E links to full P/E history page with 30-year chart
CDNA EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.52 | 3.37 | 2.13 | 1.73 | 6.91 | 16.92 | 6.90 | 10.86 | 3.90 | 1.26 |
| EV / EBITDA | — | — | 18.60 | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | 26.53 | 35.67 | — | — | — | 140.91 | — | — | — | — |
CDNA Profitability
Margins and return-on-capital ratios measuring operating efficiency
CareDx, Inc earns an operating margin of -5.5%. Operating margins have expanded from -72.5% to -5.5% over the past 3 years, signaling improving operational efficiency. A negative ROE of -6.3% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 67.0% | 67.0% | 67.2% | 63.6% | 65.1% | 67.1% | 67.2% | 64.2% | 56.9% | 55.8% | 48.0% |
| Operating Margin | -5.5% | -5.5% | 12.2% | -72.5% | -24.0% | -10.0% | -11.7% | -19.3% | -20.3% | -42.0% | -91.9% |
| Net Profit Margin | -5.6% | -5.6% | 15.7% | -67.9% | -23.8% | -10.3% | -9.7% | -17.3% | -61.1% | -114.8% | -97.1% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -6.3% | -6.3% | 16.4% | -55.0% | -17.1% | -8.2% | -9.9% | -22.5% | -103.9% | -803.5% | -160.3% |
| ROA | -4.7% | -4.7% | 11.0% | -37.7% | -13.8% | -6.6% | -7.2% | -15.6% | -43.6% | -69.2% | -59.6% |
| ROIC | -5.7% | -5.7% | 12.1% | -51.4% | -22.3% | -14.9% | -14.9% | -37.7% | -54.7% | -80.8% | -133.9% |
| ROCE | -5.8% | -5.8% | 10.3% | -47.5% | -16.2% | -7.5% | -10.8% | -21.5% | -20.5% | -53.0% | -91.7% |
CDNA Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $65M exceeds total debt of $20M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.06 | 0.06 | 0.07 | 0.13 | 0.09 | 0.05 | 0.07 | 0.05 | 0.00 | — | 1.21 |
| Debt / EBITDA | — | — | 0.47 | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.15 | -0.23 | -0.18 | -0.12 | -0.70 | -0.42 | -0.33 | -0.67 | — | 0.34 |
| Net Debt / EBITDA | — | — | -1.43 | — | — | — | — | — | — | — | — |
| Debt / FCF | — | -1.27 | -2.73 | — | — | — | -5.05 | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | -4.21 | -3.13 | -13.32 |
Net cash position: cash ($65M) exceeds total debt ($20M)
CDNA Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
CareDx, Inc's current ratio of 2.86x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 4.02x to 2.86x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.86 | 2.86 | 3.94 | 4.02 | 5.10 | 5.61 | 3.95 | 2.07 | 4.16 | 0.62 | 0.65 |
| Quick Ratio | 2.56 | 2.56 | 3.72 | 3.77 | 4.85 | 5.38 | 3.80 | 1.89 | 3.91 | 0.49 | 0.52 |
| Cash Ratio | 1.97 | 1.97 | 2.92 | 3.02 | 3.86 | 4.51 | 3.25 | 1.10 | 3.31 | 0.39 | 0.42 |
| Asset Turnover | — | 0.92 | 0.68 | 0.60 | 0.59 | 0.52 | 0.52 | 0.84 | 0.59 | 0.58 | 0.53 |
| Inventory Turnover | 4.70 | 4.70 | 5.62 | 5.24 | 5.83 | 5.67 | 6.30 | 7.56 | 6.67 | 3.87 | 3.87 |
| Days Sales Outstanding | — | 40.97 | 70.65 | 66.48 | 75.22 | 73.59 | 65.76 | 69.10 | 46.53 | 22.59 | 24.87 |
CDNA Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
CareDx, Inc returns 7.9% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 4.3% | — | — | — | — | — | — | — | — |
| FCF Yield | 3.3% | 3.6% | 2.6% | — | — | — | 0.7% | — | — | — | — |
| Buyback Yield | 7.9% | 8.7% | 0.0% | 4.3% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 7.9% | 8.7% | 0.0% | 4.3% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $53M | $57M | $54M | $53M | $52M | $46M | $42M | $36M | $23M | $16M |
Peer Comparison
Compare CDNA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 CDNAYou | $1B | -53.6 | — | 30.7 | 67.0% | -5.5% | -6.3% | -5.7% | — |
 NTRA | $31B | -144.6 | — | 285.5 | 64.8% | -13.4% | -14.3% | -36.1% | — |
 EXAS | $20B | -95.4 | — | 56.1 | 69.7% | -6.4% | -8.7% | -3.6% | — |
 PACB | $498M | -0.9 | — | — | 31.7% | -348.5% | -213.5% | -45.8% | — |
 ILMN | $21B | 25.5 | 19.6 | 22.6 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
 TXMD | $23M | -10.6 | — | 31.8 | 100.0% | -270.3% | -7.7% | -11.4% | — |
 FLGT | $449M | -7.7 | — | — | 40.6% | -28.2% | -5.4% | -6.4% | — |
 VCYT | $3B | 49.7 | 30.7 | 25.7 | 69.6% | 14.3% | 5.3% | 5.6% | 0.4 |
 PGNY | $2B | 29.5 | 16.4 | 8.2 | 23.6% | 6.6% | 12.5% | 18.1% | 0.3 |
 CSTL | $583M | -23.2 | — | 20.6 | 68.7% | -12.4% | -5.2% | -8.5% | — |
 TMO | $176B | 26.8 | 19.0 | 28.0 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 14 years · Updated daily
See CDNA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CDNA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CDNA vs NTRA
Side-by-side business, growth, and profitability comparison vs Natera, Inc..
Start ComparisonCDNA — Frequently Asked Questions
Quick answers to the most common questions about buying CDNA stock.
What is CareDx, Inc's P/E ratio?
CareDx, Inc's current P/E ratio is -53.6x. The historical average is 47.8x.
What is CareDx, Inc's ROE?
CareDx, Inc's return on equity (ROE) is -6.3%. The historical average is -36.7%.
Is CDNA stock overvalued?
Based on historical data, CareDx, Inc is trading at a P/E of -53.6x. Compare with industry peers and growth rates for a complete picture.
What are CareDx, Inc's profit margins?
CareDx, Inc has 67.0% gross margin and -5.5% operating margin.